Skip to content

Moderate Weight Loss Makes Obese Patients With Severe Chronic Plaque Psoriasis Responsive to Sub-Optimal Dose of Cyclosporine: an Investigator Blinded, Controlled, Randomized Clinical Trial

Moderate Weight Loss Makes Obese Patients With Severe Chronic Plaque Psoriasis Responsive to Sub-Optimal Dose of Cyclosporine: an Investigator Blinded, Controlled, Randomized Clinical Trial

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00512187
Enrollment
Unknown
Registered
2007-08-07
Start date
2005-11-30
Completion date
2007-08-31
Last updated
2007-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Plaque Psoriasis, Obesity

Brief summary

The study hypothesis is to investigate whether a moderate weight loss (i.e. a weight reduction of at least 5%) could improve the response rate to a suboptimal dose of cyclosporine in patients with severe psoriasis.

Interventions

OTHERlow calorie diet

Low calorie diet was designed to achieve a loss of 5-10% of initial weight. All enrolled patients received a balanced diet scheme, based on a caloric intake reduction related to BMI and sex (range 1200-1500 Kcal/day for women, 1300-1600 Kcal/day for men). Calorie intake consisted approximately of 60% carbohydrates, 25% fat, 15% protein

Sponsors

Universita di Verona
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* 18 years of age,active but clinically stable plaque psoriasis involving at least 10 percent of the body surface area and a psoriasis area and severity index (PASI) score ≥10 and a body mass index ≥30.

Exclusion criteria

* Other type of psoriasis (guttate, erythrodermic and pustular psoriasis) * Uncontrolled hypertension * Severe congestive heart failure * Renal and liver impairment * Active or chronic infections, including HIV, HBV and HCV infections, latent tuberculosis * Previous or active malignancies * Pregnancy and lactations * Previous treatment with cyclosporine * Phototherapy or any systemic or topical therapy for psoriasis within the previous 4 weeks before enrolment.

Design outcomes

Primary

MeasureTime frame
Primary end point PASI 75 responseweek 24

Secondary

MeasureTime frame
secondary end point was % of body weight reductionweek 24

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 4, 2026